Ultragenyx Pharmaceutical (RARE) Stock Overview
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
RARE Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.72 |
| 52 Week High | US$43.54 |
| 52 Week Low | US$18.41 |
| Beta | 0.15 |
| 1 Month Change | -6.15% |
| 3 Month Change | -32.23% |
| 1 Year Change | -45.70% |
| 3 Year Change | -47.72% |
| 5 Year Change | -84.05% |
| Change since IPO | -46.22% |
Recent News & Updates
Recent updates
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
Jan 22The Market Doesn't Like What It Sees From Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Yet As Shares Tumble 43%
Dec 30
Is Ultragenyx Pharmaceutical (NASDAQ:RARE) Using Too Much Debt?
Oct 28Why Investors Shouldn't Be Surprised By Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Low P/S
Jul 03Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
May 08Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt
Apr 07
FDA Progress Will Accelerate Approval Of UX111 And UX143 In 2025
Global expansion and gene therapy product approvals are positioned to significantly enhance revenue streams and overall earnings.Ultragenyx Pharmaceutical: Advancing On Multiple Fronts
Jan 29Does Ultragenyx Pharmaceutical (NASDAQ:RARE) Have A Healthy Balance Sheet?
Dec 31Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Nov 12Ultragenyx: Excellent Company, Lackluster Stock
Nov 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Shareholder Returns
| RARE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.7% | 1.0% | 1.0% |
| 1Y | -45.7% | 26.2% | 14.6% |
Return vs Industry: RARE underperformed the US Biotechs industry which returned 26.2% over the past year.
Return vs Market: RARE underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| RARE volatility | |
|---|---|
| RARE Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RARE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RARE's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,371 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| RARE fundamental statistics | |
|---|---|
| Market cap | US$2.19b |
| Earnings (TTM) | -US$575.00m |
| Revenue (TTM) | US$673.00m |
Is RARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RARE income statement (TTM) | |
|---|---|
| Revenue | US$673.00m |
| Cost of Revenue | US$859.00m |
| Gross Profit | -US$186.00m |
| Other Expenses | US$389.00m |
| Earnings | -US$575.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.96 |
| Gross Margin | -27.64% |
| Net Profit Margin | -85.44% |
| Debt/Equity Ratio | -1,665.8% |
How did RARE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/23 08:00 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ultragenyx Pharmaceutical Inc. is covered by 34 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |